Abstract
'Early-onset' studies have shown that symptomatic response often occurs early and that early symptomatic response is predictive for later outcome. Limiting factors of these studies include the restriction on symptomatic outcome, the inclusion of mostly moderately ill patients, and the use of various antipsychotics. Response and remission rates were assessed in 528 severely ill patients with schizophrenia at baseline, week 2, 4 and 12 using PANSS, SWN-K, CGI-S, and SOFAS. The clinical measures were combined to one outcome criterion (CombOut). Predicitive validity was analyzed for CombOut using linear regression models. Rate and time to response differed markedly between outcome measures. 32% reached positive symptom response at week 2, 58% at week 4 and 85% at week 12. Non-response at week 4, but not at week 2 was predictive for later non-response. The combined outcome criterion was best predicted by early response in subjective wellbeing (T=-7.88, p<0.001) and social functioning (T=-7.43, p<0.001). Rate and time to response might depend on sample characteristics and outcome measure. In severely ill patients early antipsychotic response is possibly delayed from the first 2 to the first 4 weeks. Early response in subjective wellb...Continue Reading
Citations
Jan 1, 1983·Immunology Letters·G FórisG A Medgyesi
Apr 29, 1986·Biochimica Et Biophysica Acta·I Nagaoka, T Yamashita
Nov 26, 2013·Journal of Child and Adolescent Psychopharmacology·Marie Stentebjerg-OlesenChristoph U Correll
Mar 28, 2013·Annals of General Psychiatry·Philip GorwoodUNKNOWN Europe, Middle East and Africa functioning group
Mar 29, 2011·The Australian and New Zealand Journal of Psychiatry·Sylke VothknechtLieuwe de Haan
May 19, 2012·Expert Opinion on Pharmacotherapy·Stefania RuiuGiorgio Marchese
May 17, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·A KarowUNKNOWN EGOFORS Initiative
May 17, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·A KarowUNKNOWN EGOFORS Initiative
Jan 25, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rebecca Schennach-WolffMichael Riedel
Jun 4, 2015·Psychiatry and Clinical Neurosciences·Kotaro Hatta
Aug 21, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Dieter NaberJosep Maria Haro
Mar 31, 2015·Comprehensive Psychiatry·In-Jo ParkYong Sik Kim
Oct 2, 2012·Psychiatry Research·Sylke VothknechtUNKNOWN For GROUP (Genetic Risk and Outcome of Psychosis)
Jan 7, 2011·The International Journal of Neuropsychopharmacology·Stefan LeuchtJohn M Davis
Aug 9, 2016·Acta Psychiatrica Scandinavica·F WartelsteinerA Hofer
Dec 9, 2016·The International Journal of Neuropsychopharmacology·Steven G PotkinDieter Naber
Jan 17, 2014·Journal of Psychopharmacology·Stefan Leucht, Jun Zhao
Feb 5, 2011·Journal of Psychopharmacology·Thomas R E Barnes, UNKNOWN Schizophrenia Consensus Group of British Association for Psychopharmacology
Jun 30, 2018·BMC Psychiatry·Christian G WidschwendterAlex Hofer
Dec 5, 2018·CNS Drugs·A George Awad
Jul 15, 2021·Schizophrenia Research. Cognition·Daniel KrzyzanowskiGary Remington
Aug 15, 2021·Neuropsychopharmacology Reports·UNKNOWN Japanese Society of Neuropsychopharmacology
Jul 27, 2010·Schizophrenia Research·Rajiv TandonMatcheri S Keshavan